This is a well written and much-needed pilot trial. In particular, the pragmatic approach is likely to identify real world methodological and treatment-related issues that may require modification and consideration in a future clinical trial and the authors are commended for this approach and its justification. The authors have also described and justify a considerable portion of their methods. However, a few comments and suggestions regarding the methodology remain and are outlined below: 1. The primary objective of the study, described by the authors on page 5 (lines 28-29 and lines 53-54) "To evaluate the effectiveness of acupuncture …." does not match the design or intent of a pilot study. It is well recognised, including in the CONSORT extension for pilot randomised controlled trials, that pilot studies are not designed to provide a preliminary test of efficacy but rather assess the feasibility of conducting the future definitive RCT. This should be recognised in the aims throughout this pilot study and abstract and greater emphasis placed on feasibility aspects recommended in the CONSORT extension for example: a. Number of participants screened b. Number of participants eligible (including reasons for exclusion) c. Number of participants consenting (including reasons for not consenting if appropriate) d. Time taken to recruit target number of participants etc.
need to be based on efficacy calculations, the authors should justify a number that is sufficient to achieve their aim. For example, if they aim to just explore aspects of feasibility and implementation, the suggested 15 per group may be justified if they consider it a sample large enough to account for the variability in presentations/ diagnoses and individualised treatments they are likely to encounter. However, if their aim remains to be for efficacy and safety reasons, then they need to justify a sample large enough to detect the effect size they are after or justified a sample size large enough to detect risks/adverse events (safety objective).
3. Inclusion criteria: There appears to be a discrepancy with the inclusion criteria. On page 8, lines 16 specify inclusion of participants with NRS ≥ 4, while the flow chart on page 7 indicates participants are ineligible if their NRS<7. This needs amendment.
4. Intervention: a. Greater details surrounding the acupuncturist would benefit replicability of the trial. Who is the licensed acupuncturist (page 9, line 8) relative to the unit or participants? Please clarify if the acupuncturist is providing any other therapies to participants as part of usual care that may influence the therapeutic alliance. For replicability and considering a large component of the intervention is individual tailoring, please also clarify the expertise and experience of the acupuncturist providing the treatment and if it is a single acupuncturist or there are multiple treatment providers.
b. Intervention protocol: It is excellent to see the intervention has been designed in consultation with experts in the field. While this is briefly referred to on page 9 lines 21: "Delphi expert consensus based on the most frequently-used and effective acupuncture points in pre-modern literature and clinical trials of acupuncture for cancer pain" further details including a reference to this Delphi study (if published) or an appendix with a summary of these aspects (i.e. questions put to experts, numbers and key demographics and key findings) would strengthen the protocols selected.
c. Intervention: How will intervention fidelity be assessed (i.e. adherence to the five standardised acupuncture points). Will a therapist log be utilised and who will evaluate/assess for intervention fidelity? 5. Data collection: a. The authors specify on page 10, lines 5-6 that "detailed information on the procedures for controlling pain will be reported and documented" could the authors please clarify if this information will be collected prospectively with a data collection form or if it will be collected retrospectively from patient records and by whom? b. Page 10, lines 46-51, the authors specify: The researchers will collect individual data accurately into the pre-designed CRF. Pain intensity ratings will be obtained every 60 minutes for participants taking oral opioids or every 15 minutes for those receiving intravenous bolus during opioid titration". Could the authors confirm if these researchers will be blinded or only those conducting follow up measures? c. How will the success of independent assessor blinding be evaluated? 6. Statistical analyses: a. How withdrawn and missing data is managed. The authors have indicated on page 8, lines 36-37 that "withdrawn cases who have received the intervention will be contact for a 2-week follow-up period to obtain data…". Could the authors please clarify how analyses will manage participants who withdraw and decline further contact or participants who have withdrawn after randomisation, but prior to receiving the intervention.
b. How will missing data be managed? c. The authors should consider if they have sufficient numbers to warrant a subgroup analysis and what the intent of this would be (page 12, lines 7-9).
d. The statistical analyses need to reflect the intent of pilot studies (As per initial comment). Hence, greater emphasis should be placed on reporting of effect sizes as opposed to statistical significance as per CONSORT extension recommendations.
e. Who will conduct data analysis, data input and cleaning processes?
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GENERAL COMMENTS
In the abstract the sample size should be specified In the figure 1: patients are included only if they have NRS>7?In the text the author specified that patients with moderate-severe pain could be recruited, I think it should be corrected (eligible patients (NRS> or = 5). In the figure 1 I would specifiy that patients with cognitive impairment were excluded, Further I think that data collected at T0 should specified and pain measurement should be registered in the CRF every day (from day 1 to day 6). The authors acknowledge the risk of bias in non-blinded studies in the Introduction, but then proceed to propose a non-blinded study without fully recognizing the contradiction. Indeed they seem to elide the issue of whether the theorized mechanism of action of acupuncture actually works by calling their study a pragmatic trial, which implicitly forgoes the idea of determining why something works to just see whether it works. In this context, any positive results could be entirely explained by a placebo effect, in this case by the fact that patients feel better because they are aware of the extra attention of acupuncture sessions and this improves their well being and associated outcomes (pain), irrespective of whether the mechanism of acupuncture actually works. The addition of acupuncture to existing opioid use is of interest. Fifteen patients per arm is insufficient to determine any but the most extreme differences given limited power, especially given the heterogeneity of the sample. In the Discussion, Limitations, the authors indicated that, "If there is a trend, the results can be used to estimated the power required for a larger study." The protocol contains no specification of any decision rule regarding at point a "trend" is observed.
The authors indicate that, "Participants and practitioners involved in the study will not be blinded. However, the researchers collecting primary data and performing statistical analysis will be blinded to the participant's allocation." The important issue is clearly to blind the patients, since they are providing the endpoint data. To suggest that the researchers performing the statistical analysis will be blinded to the participant's allocation seems implausible (since it will generally be clear from the data, even absent the explicit randomization assignment). Moreover, although perhaps an admirable step, I wonder how necessary it is given this is not a large pharma study seeking a new drug indication.
The protocol is well written so is fine in that regard, however given this is such a small pilot trial and the design is somewhat dubious I wonder how important it is to first publish the protocol, or just wait to publish the findings alongside a description of the design.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Comment 1: The primary objective of the study, described by the authors on page 5 (lines 28-29 and lines 53-54) "To evaluate the effectiveness of acupuncture …." does not match the design or intent of a pilot study. It is well recognised, including in the CONSORT extension for pilot randomised controlled trials, that pilot studies are not designed to provide a preliminary test of efficacy but rather assess the feasibility of conducting the future definitive RCT. This should be recognised in the aims throughout this pilot study and abstract and greater emphasis placed on feasibility aspects recommended in the CONSORT extension for example: Response: Thank you for the suggestions. The abstract and objectives of this trial have been amended. The word "feasibility" has been highlighted in the abstract and objectives, while the word "effectiveness" has been removed (the revised version page 2, lines 6-9 and page 4, lines 21-24). The first specific objective is stated as to "Investigate the proportions of participants confirmed as screened, eligible and consenting (including reasons for exclusion), and the time required to recruit the target number of participants" and the rest objectives all focus on the feasibility aspects recommended in the CONSORT extension for reporting a pilot trial (revised version page 4, line 25 to page 5, line 5).
Comment 2: Sample size: There is very little reporting throughout of the target sample. On page 8 the authors comment that "a sample size calculation is not required" is inconsistent with their intent to evaluate efficacy. While the sample size for pilot studies does not need to be based on efficacy calculations, the authors should justify a number that is sufficient to achieve their aim. For example, if they aim to just explore aspects of feasibility and implementation, the suggested 15 per group may be justified if they consider it a sample large enough to account for the variability in presentations/ diagnoses and individualised treatments they are likely to encounter. However, if their aim remains to be for efficacy and safety reasons, then they need to justify a sample large enough to detect the effect size they are after or justified a sample size large enough to detect risks/adverse events (safety objective).
Response: Thank you for highlighting these issues. The aim to explore feasibility for the full-scale trial has been clarified in the revision and the statement about sample size has been justified: "Since the study is a pilot study, a formal sample size calculation is not required [33] . One analysis identified 12 participants per group as an appropriate sample in a feasibility study [34] . Another study calculated that power could be adequate for moderate effect sizes at 15 per group [35] . Considering a 25% dropout rate [36], we selected 15 participants per group for this pilot trial. As the short duration (3 weeks) of the proposed study and the high degree of cultural acceptability of acupuncture in the proposed participant population, it appears likely that the dropout rate could be lower than 25% [37]" (revised version page 6, line 30 to page 7, line 5).
Comment 3: Inclusion criteria: There appears to be a discrepancy with the inclusion criteria. On page 8, lines 16 specify inclusion of participants with NRS ≥ 4, while the flow chart on page 7 indicates participants are ineligible if their NRS<7. This needs amendment.
Response: Thank you for noticing this error. The inclusion criteria should be NRS ≥ 4 and the error in the flow chart has been amended.
Comment 4: Intervention:
a. Greater details surrounding the acupuncturist would benefit replicability of the trial. Who is the licensed acupuncturist (page 9, line 8) relative to the unit or participants? Please clarify if the acupuncturist is providing any other therapies to participants as part of usual care that may influence the therapeutic alliance. For replicability and considering a large component of the intervention is individual tailoring, please also clarify the expertise and experience of the acupuncturist providing the treatment and if it is a single acupuncturist or there are multiple treatment providers.
Response: We have added some details about the acupuncturist as "One licensed acupuncturist with more than three years' acupuncture experience will provide acupuncture treatment to all participants. The acupuncturist will not be, or have been, involved in any other aspect of the treatment of the participants. Apart from acupuncture, other therapies related to stimulating acupuncture points such as acupressure, moxibustion and transcutaneous electrical nerve stimulation (TENS) are not allowed during this trial" (revised version page 7, lines 24-29).
Response: We have added extra information in the text "Twenty-two acupuncturists from the China Association of Acupuncture and Moxibustion and three international acupuncturists with extensive acupuncture experience participated in the survey by questionnaires. Significant agreement was achieved on the necessity of individualized acupuncture protocols and the effectiveness of Hegu(LI4), Taichong(LR3), Zusanli(ST36), Sanyinjiao(SP6) and Yanglingquan(GB34) in pain alleviation". The relevant information has been added on page 8, lines 4-13 in the revised manuscript and two supplementary documents have been attached. c. Intervention: How will intervention fidelity be assessed (i.e. adherence to the five standardised acupuncture points). Will a therapist log be utilised and who will evaluate/assess for intervention fidelity?
Response: Thank you for this question. We have provided further data. "The whole process of acupuncture treatment will be supervised by another researcher for double-checking the acupuncture point selection and standard operating procedure. Details of acupuncture therapies (e.g., number and specification of needles used, specific acupuncture points applied, and duration of the therapies) will be recorded in the Acupuncture treatment record section of the Case Record Form (CRF, Supplementary 3) by the acupuncture supervisor and signed off by the acupuncturist." The operation of fidelity assessment for acupuncture has been specified on page 8, lines 24-30.
Comment 5: Data collection:
a. The authors specify on page 10, lines 5-6 that "detailed information on the procedures for controlling pain will be reported and documented" could the authors please clarify if this information will be collected prospectively with a data collection form or if it will be collected retrospectively from patient records and by whom?
Response: It has been clarified that "Detailed information on the procedures for controlling pain will be collected retrospectively from patients' Electronic Medical Record (EMR) and transferred to the Analgesic treatment records section in the CRF by the data administrator" (revised version page 9, lines 14-16).
b. Page 10, lines 46-51, the authors specify: The researchers will collect individual data accurately into the pre-designed CRF. Pain intensity ratings will be obtained every 60 minutes for participants taking oral opioids or every 15 minutes for those receiving intravenous bolus during opioid titration". Could the authors confirm if these researchers will be blinded or only those conducting follow up measures?
Response: "An independent data administrator blinded to the group allocation and not involved in the treatment will collect individual data accurately into the Pain assessment records in the CRF. Pain intensity ratings will be obtained every 60 minutes for participants taking oral opioids or every 15 minutes for those receiving intravenous bolus during opioid titration. When pain is stable over time, participants will be asked to assess the pain intensity twice a day, namely early in the morning at 8am and late in the afternoon at 6pm. The time of acupuncture treatment and pain assessment will be staggered in order to ensure the blindness of the data administrator. Analgesic consumption, frequency of breakthrough pain and rescue medication used, adverse events and withdrawals or dropouts for any reason will be recorded in the Analgesic treatment records, Records of Medications and Other Therapies and Reports of Adverse Events in the CRF by the data administrator." These details have been confirmed on page 10, lines 22-33 in the revision.
c. How will the success of independent assessor blinding be evaluated?
Response: Thank you for this question. We have learned from the method of blinding evaluation in your trial protocol and revised our manuscript as "Participants and practitioners involved in the study will not be blinded. However, the researchers collecting primary data and performing statistical analysis will be blinded to the participant's allocation. The success of blinding for assessors will be assessed by the answers to the question: 'which group do you believe this participant belongs to?'" on page 7, lines 15-19.
Comment 6: Statistical analyses:
a. How withdrawn and missing data is managed. The authors have indicated on page 8, lines 36-37 that "withdrawn cases who have received the intervention will be contact for a 2-week follow-up period to obtain data…". Could the authors please clarify how analyses will manage participants who withdraw and decline further contact or participants who have withdrawn after randomisation, but prior to receiving the intervention.
Response: Thank you for raising this issue. "Participants who withdraw and decline further contact, including participants who have withdrawn after randomisation but prior to receiving the intervention are defined as dropouts. Data from dropout cases will be managed by both per-protocol (PP) analysis and intention-to-treat analysis (ITT) to evaluate the influence of missing data." More details on statistical analyses have been indicated on page 9, line31 to page 10 line 2.
b. How will missing data be managed?
Response: As the response to the comment above, missing data will be managed by both perprotocol (PP) analysis and intention-to-treat analysis (ITT) to evaluate their influence.
c. The authors should consider if they have sufficient numbers to warrant a subgroup analysis and what the intent of this would be (page 12, lines 7-9).
Response: Originally, subgroup analyses for cancer-specific comparisons, number of sessions of acupuncture treatment were supposed to optimize design for a further study with regard to inclusion criteria and intervention protocol. However, considering the small sample size in this pilot trial, it is likely it will not provide sufficient number for subgroup analysis, so this sentence has been deleted.
Response: Thank for this recommendation. In accordance with the CONSORT extension recommendations, the text has been revised (page 11, lines 10-14) by stating that "The primary analysis of this pilot trial will focus on the outcomes assessing feasibility by descriptive analysis. The number and the proportion of participants recruited, screened, consented and randomised will be presented. The characteristics of participants, number and reasons for withdrawals from the trial, and adverse events will be summarised for each group".
Response: Thank you for this question. We have clarified this.
"All data entry will use anonymous sheets and statistical analysis will be undertaken by an independent statistician blinded to treatment allocation using the Statistical Package for the Social Sciences (SPSS)" (revised version page 11 lines 23-25).
Reviewer: 2 Comment 1: In the abstract the sample size should be specified
Response: Thank you. The revised abstract now states the pilot trial will include 30 participants (revised version page 11 line 11).
Comment 2: In the figure 1: patients are included only if they have NRS>7?In the text the author specified that patients with moderate-severe pain could be recruited, I think it should be corrected (eligible patients (NRS> or = 5). In the figure 1 I would specify that patients with cognitive impairment were excluded, further I think that data collected at T0 should specified and pain measurement should be registered in the CRF every day (from day 1 to day 6).
Response: Thank you for your detailed comments. These errors have been corrected. The flow chart and the text have been revised according to your advice.
Comment 3: Page 8 line 24: I think that risky medical conditions should be better specified
Response: Thank you for this recommendation. The exclusion criteria have been specified as "severe and unstable clinical disorders" rather than "risky medical condition" with examples (revised version page 6 line 17).
Comment 4: Sample size calculation: I think it should be better explained the sample size prediction (which statistical power will you reach with 15 patients in each group??)
Response: Sample size calculation has been better clarified as "Since the study is a pilot study, a formal sample size calculation is not required [33] . One analysis identified 12 participants per group as an appropriate sample in a feasibility study [34] . Another study calculated that power could be adequate for moderate effect sizes at 15 per group [35] . Considering a 25% drop-out rate [36], we selected 15 participants per group for this pilot trial. Considering the short duration (3 weeks) of the proposed study and the high degree of cultural acceptability of acupuncture in the proposed participant population, it appears likely that the dropout rate could be lower than 25% [37]" (revised version page 6, line 30 to page 7, line 5).
Comment 5: Page 9 line 35: how can you predict to have a good level of analgesia within 4-6 days? If the goals of analgesia are not achieved will you continue with once a day acupuncture? will you exclude the patient?
Response: Thank you for this question. According to our clinical experience in the oncology department, the majority of patients could achieve the analgesic goal within 48 hours. However, in order to ensure that all participants receive the same number of acupuncture sessions, it is stipulated that acupuncture will be delivered on Day 1/2/4/6. If pain cannot be controlled within 48 hours after pain management, specialty consultation will be considered and the participant will be withdrawn. The relevant contents in the manuscript have been revised (revised version page 8, lines 20-22 and page 9, lines 8-10).
Comment 6: Page 10 line 33: why do you want to assess other symptoms through the ESAS? Do you assume the acupuncture could be effective in other symptoms management? I think it should be explained.
Response: We had intended to use ESAS to explore the possible effect of acupuncture on the improvement of opioid-related symptoms. However, the ESAS is a scale assessing general symptoms for cancer patients and the outcome "Adverse events" may well be competent to record side effects of the treatments. So we decided to remove the ESAS from the clinical outcome measurements to keep the trial focused on acupuncture for cancer pain symptoms. Response: Yes, exactly. During the follow-up period, participants are required to record their pain intensity, analgesic consumption, frequency of breakthrough pain and rescue medication use, as well as adverse events in the CRF every day. They will be contacted by telephone every day as a reminder (revised version page 11, lines 4-8).
Comment 9: I really appreciated this study protocol, I think this is a rigorous method and I hope you could include a significative number of patients in order to reach strong results.
Response: Thanks for your comment. Obviously, the relatively small sample size is one of limitations of this pilot trial. We will definitely try to solve the practical problems encountered in the pilot study and include enough participants in the full trial.
Reviewer: 3
With respect to the presentation of the protocol, it was well written and clear.
With respect to the content of the design, I had the following comments:
Comment 1: In the Introduction, the authors should consider citing a recent study from JAMA showing significant pain relief for women receiving aromatase inhibitor therapy for breast cancer. Hershman et al., JAMA, 2018.
Response: Thank you for your suggestion. This study has been cited in the revised background with the statement that "A rigorous large-scale randomised controlled trial published recently reported that true acupuncture, compared with sham acupuncture or with waitlist control, resulted in a significant reduction in aromatase inhibitor-related joint pain among women with breast cancer" (revised version page 3, line 30 to page 4, line 2).
Comment 2: The authors acknowledge the risk of bias in non-blinded studies in the Introduction, but then proceed to propose a non-blinded study without fully recognizing the contradiction. Indeed they seem to elide the issue of whether the theorized mechanism of action of acupuncture actually works by calling their study a pragmatic trial, which implicitly forgoes the idea of determining why something works to just see whether it works. In this context, any positive results could be entirely explained by a placebo effect, in this case by the fact that patients feel better because they are aware of the extra attention of acupuncture sessions and this improves their well being and associated outcomes (pain), irrespective of whether the mechanism of acupuncture actually works. The addition of acupuncture to existing opioid use is of interest.
Response: Indeed, this was not well written. We recognise the issue but at this stage, we aim to design a pragmatic randomised controlled trial to determine if any effect is measurable in the realworld setting, rather than consider the efficacy or mechanism of acupuncture. We agree that investigation of any mechanisms of acupuncture is important, but this study was primarily motivated by the practical need to maximize the provision of pain relief to our patients without wasting resources. If the protocol proves feasible and a larger scale study is conducted it may find that acupuncture has no additional effect in pain relief and does not reduce opioid dosage. If so, the hospital will not spend money providing acupuncture in-house for cancer pain relief. Conversely, there may be a measurable effect. Either way, the study will not determine the efficacy or mechanism of acupuncture, but it will provide useful data for hospital decision makers. Assuming an effect, it may be possible to conduct a more rigorous sham-controlled study at the later date.
